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MaCardiac resynchronization therapy (CRT) is an accepted treatment for patients with heart failure (HF), impaired left
ventricular (LV) function, and a wide QRS complex. It has been revolutionary for patients with advanced HF whose only
previous option was cardiac transplantation, and it is now a realistic option for patients with mild HF. The development
of CRT also has united the previously disparate cardiological subspecialties of electrophysiology and HF. This review,
written on the occasion of the 20th anniversary of the ﬁrst clinical use of CRT for HF, takes a historical perspective
on CRT’s evolution from “bench to bedside.” We also comment on the task faced by electrophysiologists and HF
specialists as they make this life-saving therapy available to an increasing number of eligible patients. (J Am Coll Cardiol
2014;64:1047–58) © 2014 by the American College of Cardiology Foundation.C ardiac resynchronization therapy (CRT) is anaccepted treatment for patients with heartfailure (HF), impaired left ventricular (LV)
function, and a wide QRS complex. This therapy has
been no less than revolutionary for patients with
advanced HF whose only previous option was cardiac
transplantation. Now, CRT is also a realistic option for
patients with mild HF.
The recognition in 1925 that conduction distur-
bances lead to LV dysfunction (1) can be traced to ex-
periments that provided the paradigm for CRT.
Pacemaker technology, designed to correct interven-
tricular (VV) and intraventricular conduction dis-
turbances, was eventually tested in randomized,
controlled CRT trials, driven by engineers, clinicians,
and the industry. In addition to transforming patient
care, CRT has united the ﬁelds of electrophysiology
andHF, once far-removed cardiological subspecialties.
This year marks the 20th anniversary of the ﬁrst
clinical use of CRT for HF (2,3). In this historical re-
view, we review the evolution of CRT, from “bench to
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THE PRE-CRT ERA: BUILDING THE PARADIGM
In 1925, Wiggers (1) showed that surface stimulation
of the canine myocardium reduced the maximal LV
pressure derivative (LV dP/dtmax) and lengthened
isometric contraction. He proposed that this effect
and the degree of “asynchrony” depend on how much
myocardium is activated before excitation of the
Purkinje system.
When regional wall function became quantiﬁable
with radionuclide ventriculography in the 1980s,
Grines et al. (4) described how a left bundle branch
block (LBBB) reduced the diastolic ﬁlling time and the
septal contribution to LV ejection. By the 1990s, a link
emerged between electrical dyssynchrony and LV
function, in which conducting tissue disturbances give
way to conduction through the slower conducting
myocardium (Figure 1), wasted work, and a reductionniversity of Birmingham, Edgbaston, Birmingham,
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
AV = atrioventricular
CMR = cardiac magnetic
resonance
CRT-D = cardiac
resynchronization therapy–
deﬁbrillation
CRT-P = cardiac
resynchronization therapy–
pacing
HF = heart failure
ICER = incremental cost-
effectiveness ratio
ICD = implantable
cardioverter-deﬁbrillator
LBBB = left bundle branch
block
LV = left ventricular
LVEF = left ventricular ejection
fraction
NYHA = New York Heart
Association
OPT = optimal pharmacological
therapy
RV = right ventricular
VO2 = oxygen uptake
VV = interventricular
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1048in cardiac output (5). In this construct, inap-
propriate atrioventricular (AV) delays lead to
delayed systole and reduced diastolic ﬁlling.
Consequently, LV diastolic pressures exceed
atrial pressure and diastolic mitral regurgita-
tion. A decrease in LV preload then reduces
contraction via the Starling mechanism. Sys-
tolic mitral regurgitation also occurs as a
result of mitral valve ring dilation, LV
remodeling, and papillary muscle dyssyn-
chrony. Other, more recently described ef-
fects of CRT are shown in Figure 2.
EARLY CRT STUDIES:
PROOF OF CONCEPT
By the 1990s, it was apparent that LV pacing
was more hemodynamically favorable than
right ventricular (RV) pacing, but there was
little interest in abandoning the traditional
pacing site. Befeler et al. (6) ﬁrst described
temporary, simultaneous biventricular pac-
ing to assess arrhythmias. In 1983, de Teresa
et al. (7) ﬁrst reported sequential AV pacing
of the left ventricle in patients with AV block
and LBBB, and without HF. Key ﬁndings were
that simultaneous septal and LV free wall
contraction was hemodynamically superior
to dyssynchronous contraction and that the
best hemodynamic effect arose from fusionbetween intrinsic LBBB conduction and the LV pacing
stimulus.
In 1987, Mower devised and was granted a patent
for the concept of “biventricular pacing,” explicitly
aimed at HF treatment. Mower conceived biven-
tricular pacing as a method of pacing both ventricles
after a predetermined AV interval. Two electrodes
would be connected in series, 1 in the right ventricle
and another around the LV free wall. Bakker’s group
(8) subsequently used a dual-chamber pacemaker
with a Y adapter to treat 12 patients with HF. This case
series (8), which began in 1993, showed that biven-
tricular pacing improved functional capacity and
LV function. Cazeau et al. (3) subsequently described
a 4-chamber pacing system that reduced pulmonary
capillary wedge pressure and increased cardiac
output. This group (9) later described a wholly
transvenous CRT implantation that, coupled with the
innovative over-the-wire technique of Auricchio et al.
(10), began a new era for CRT.
In 1995, Leclercq et al. (11) showed that, compared
with AAI pacing, CRT-pacing (CRT-P) led to an increase
in cardiac index and a reduction in pulmonary capillary
wedge pressure. Auricchio et al. (12) subsequentlydemonstrated that patient-speciﬁc AVdelay variations
led to changes in LV dP/dtmax and aortic pulse pres-
sure. The recognition of patient-speciﬁc variations in
response to CRT (13) is key to the current AV optimi-
zation debate and to the inﬂuence of QRS duration and
morphology on the response to CRT.
THE CORE TRIALS
In 2001, the safety and efﬁcacy of CRT were ﬁrst
addressed by both the MUSTIC (Multisite Stimulation
in Cardiomyopathies) (14) and PATH-HF (Pacing
Therapies in Congestive Heart Failure) studies (15). In
the MUSTIC study, 67 patients with HF were ran-
domized to 3 months of off or on CRT. Compared with
CRT-off, CRT-on improved walking distance, quality
of life, and peak oxygen uptake (VO2). In the PATH-HF
study (15), improvements in walking distance and
peak VO2 were observed after 12 months of biven-
tricular pacing. It was the ﬁrst study to show LV
reverse remodeling after CRT. In the MIRACLE
(Multicenter InSync Randomized Clinical Evaluation)
study (16), the ﬁrst double-blind CRT trial, 453
patients with HF were randomized to CRT-P or to no
pacing. At 6 months, CRT-P improved walking
distance, quality of life, exercise capacity, left ven-
tricular ejection fraction (LVEF) and peak VO2, paral-
leling LV reverse remodeling.
By the 2000s, secondary prevention trials began
to show a beneﬁt of implantable cardioverter-
deﬁbrillator (ICD) therapy in patients with impaired
LV function. Eight landmark primary prevention trials
demonstrated that ICDs improved survival (17). The
case for the use of ICDs in primary prevention was
evident.
The addition of CRT to ICD (CRT-deﬁbrillation
[CRT-D]) was ﬁrst explored by the MIRACLE-ICD
(Multicenter InSync ICD Randomized Clinical Evalu-
ation) study (18), in which patients with HF receiving
optimal pharmacological therapy (OPT) underwent
CRT-D and were randomized to CRT on or off. After
6 months, CRT-D led to improved quality of life and
NYHA functional class, but not walking distance.
Essentially, CRT-D led to clinical improvements
without safety concerns.
The COMPANION (Comparison of Medical Therapy,
Pacing and Deﬁbrillation in Heart Failure) trial (19)
was the ﬁrst trial to compare CRT-P and CRT-D with
OPT. Compared with OPT, CRT-P and CRT-D led to a
20% reduction in death or hospitalization from any
cause. Total mortality was least with CRT-D, and no
beneﬁt emerged for CRT-P. The incremental beneﬁt
of adding ICD to CRT was apparent. However, in a
substudy of the COMPANION study, neither CRT-P
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FIGURE 1 Mechanical Effects of LBBB
Three-dimensional representation of ventricular activation (top) and strain (bottom)
during normal activation and left bundle branch block (LBBB) in a canine heart showing
how early septal activation (blue circles) leads to early shortening (blue tracing) and
late lateral wall activation (red circle) leads to stretching in early systole followed by
shortening during the ejection phase. Gray tracings denote mean left ventricular strain.
Adapted with permission from Prinzen et al. (86) and derived from De Boeck et al. (87)
and Mills et al. (88).
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functional class IV patients (20).
The CARE-HF (Cardiac Resynchronization-Heart
Failure) study (21), which randomized patients
to OPT with or without CRT-P, showed that CRT-P
reduced death from any cause or unplanned hospital-
izations for major cardiovascular events, as well as
total mortality after 29 months. In addition, CRT-P
improved quality of life and LVEF, induced LV
reverse remodeling, and reduced mitral regurgitation.
The COMPANION trial (19) and the CARE-HF study
(21) established CRT as a treatment for HF (NYHA
functional class III or IV), impaired LV function, and a
wide QRS complex. Although the characteristics of
device-treated patients were similar, the control
group was ICD plus OPT in the COMPANION trial and
OPT only in the CARE-HF study. This may account for
the apparently lower efﬁcacy of CRT-P in the
COMPANION trial. Although some would argue on the
basis of the COMPANION trial that the treatment
effect of CRT-D is superior to that of CRT-P, others
propose that a deﬁnitive comparison is still required
because CRT-D and CRT-P were not compared.
CRT IN MILD HF
The efﬁcacy of CRT-D in mild HF was suggested by the
CONTAK CD study, which demonstrated LV reverse
remodeling across NYHA functional classes II to IV
(22). In the MIRACLE ICD II study (23), which included
patients in NYHA functional class II, CRT-D induced LV
reverse remodeling comparedwith ICD. Subsequently,
in the MADIT-CRT (Multicenter Automatic Deﬁbril-
lator Implantation Trial with Cardiac Resynchroniza-
tion Therapy) (24), which randomized 1,820 patients
in NYHA functional class I and II to CRT-D or ICD,
CRT-D reduced total mortality or HF events by 34%.
This endpoint was mainly driven by reductions in
HF events, with no difference in total mortality.
In the REVERSE (Resynchronization Reverses
Remodeling in Systolic Left Ventricular Dysfunction)
study (25), 610 patients in NYHA functional class I/II
with primary prevention ICD indications were ran-
domized to CRT-on or CRT-off. Compared with CRT-
off, CRT-on did not reduce composite HF endpoints,
nor did it improve quality of life or walking distance,
but it improved LVEF and reduced HF hospitaliza-
tions. A similar study, the RAFT (Resynchronization/
Deﬁbrillation for Ambulatory Heart Failure Trial) (26),
compared CRT-D with ICD in NYHA functional class II
or III patients. The primary endpoint of total mortality
or HF hospitalization occurred in 33.2% in the CRT-D
group and in 40.3% in the ICD group (hazard ratio:
0.75; 95% conﬁdence interval: 0.64 to 0.87).The failure of the MADIT-CRT and the REVERSE
study to demonstrate an independent effect on mor-
tality reﬂects the low background mortality (2% to
3%) in NYHA functional classes I and II. However, in
both trials, CRT led to LV reverse remodeling and a
41% to 53% reduction in HF events. Additionally, the
5-year follow-up of the REVERSE study showed a
remarkably low mortality (annualized 2.9%) in
patients randomized to CRT-on (27). Together with
the RAFT (26), these ﬁndings provide compelling
evidence for CRT in early stages of HF.
CRT AND RIGHT VENTRICULAR PACING
It has long been shown that HF is common during RV
pacing. In the DAVID (Dual Chamber and VVI
Implantable Deﬁbrillator) trial (28) and the MOST
(MOde Selection Trial) (29), RV pacing was associated
with increased HF hospitalizations, lending support
for using CRT in patients with LV dysfunction
and conventional indications for pacing (30). In
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FIGURE 2 Effects of CRT
Cardiac resynchronization therapy (CRT) has an impact on the following. 1) Transcriptome
in dyssynchronous heart failure (DHF): there is increased regional heterogeneity in gene
expression within the left ventricle that is reduced with CRT (47). 2) Mitochondrial sub-
proteome: CRT also leads to mitochondrial protein changes such as increased pyruvate
carboxylation and branched-chain amino acid oxidation, increasing the pool of Krebs cycle
intermediates and fuel oxidative phosphorylation (89). 3) CRT also improves rest and
beta-adrenergic–stimulated myocyte function and calcium handling, up-regulating beta-1
receptors and adenylate cyclase activity and suppressing Gi-coupled signaling (90).
4) Action potential: the action potential duration in DHF is more prolonged in the lateral
than in the anterior wall, and this effect is reduced by CRT, particularly in the lateral wall
(91). 5) Ventricular synchronization: CRT induces a pattern of activation different from a
left bundle branch block, with the right ventricular activation proceeding from apex to
base. The base of the right ventricle and of the interventricular septum is activated later
than in a left bundle branch block, whereas the left ventricular (LV) free wall is activated
early (92). 6) Ventricular synchronization (mechanical): DHF involves disparities in the
timing of shortening and reciprocal shortening/stretch in the anterior and lateral LV walls,
which are corrected by CRT (90). 7) Atrioventricular (AV) synchronization: when the left
ventricle is pre-excited with pacing, the start of pressure development in the left ventricle
occurs earlier. Shortening of an inappropriately long AV delay by CRT increases pulse
pressure and LV dP/dtmax. An optimal pulse pressure occurs when peak left atrial systole
coincides with the start of LV contraction (13). 8) The ﬁnal common pathway of these
actions is to alter the LV pressure-volume relationship. A leftward shift in pressure-volume
loops reﬂects reverse remodeling (93).
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1050BLOCK-HF (Biventricular Versus Right Ventricular
Pacing in Heart Failure Patients With Atrioventricular
Block) (31), 691 patients with HF and conventional
indications for pacing were randomized to CRT or
RV pacing. After 37 months, CRT was associated
with a 26% reduction in the primary composite
endpoint of total mortality, urgent HF care, or an
increase in LV end-systolic volume. Despite its limi-
tations, this study supports CRT over conventional
RV pacing in patients with LV dysfunction. More
deﬁnitive evidence is expected from the BIOPACE
(Biventricular Pacing for Atrioventricular Block to
Prevent Cardiac Desynchronization) study (32).CRT IN ATRIAL FIBRILLATION
In atrial ﬁbrillation (AF), CRT can only correct VV and
intraventricular dyssynchrony. CRT delivery is also
hampered by high intrinsic ventricular rates and
irregularity, leading to reduced capture, fusion, and
pseudofusion. Whether CRT is effective in the
context of AF is an important issue, as it occurs in up
to 25% of patients with HF in New York Heart Asso-
ciation (NYHA) functional classes II and III and in up
to 50% of patients in NYHA functional class IV (33).
Some studies have shown that CRT in AF improves
symptoms (34,35), whereas others have suggested that
it is only effective after AV junction ablation. In the
largest observational study to date, Gasparini et al. (36)
explored the outcome of CRT, in combination with
either ablation or rate-slowing drugs, in patients with
permanent AF. Over a median follow-up of 37 months,
patients receiving AF þ ablation had risks of total and
cardiac mortality comparable to those of patients in
sinus rhythm, whereas AF patients treated with drugs
had worse outcomes. Randomized data on the effects
of CRT in patients with AF are lacking.
CRT AND A NARROW QRS COMPLEX
The ﬁnding of mechanical dyssynchrony in patients
with a QRS duration <120 ms (37) provided a rationale
for extending CRT to this patient population.
Several single-center studies showed a symptomatic
beneﬁt from CRT (38–40). However, the 2 most
recent multicenter, randomized, controlled studies,
LESSER-EARTH (Evaluation of Resynchronization
Therapy for Heart Failure) trial (41) and EchoCRT
(Echocardiography Guided Cardiac Resynchronization
Therapy) (42), failed to show a mortality beneﬁt from
adding CRT to ICD in this patient group. In LESSER-
EARTH, CRT did not improve clinical outcomes or
induce LV reverse remodeling. Indeed, there was a
suggestion of potential harm. In Echo-CRT (42),
patients with a QRS duration #130 ms, LVEF #35%,
and mechanical dyssynchrony underwent CRT-D
implantation and were then randomized to CRT-on
or -off. The trial was stopped prematurely for futility
after ﬁnding increased mortality with CRT-D.
DEVICE OPTIMIZATION
The basis for device optimization is the discovery that
LV function varies according to AV delays (12).
Traditionally, echocardiography is used to identify
the AV delay yielding optimal LV ﬁlling. However,
because this technique requires exhaustive, iterative
sampling, busy departments have (not surprisingly)
abandoned AV and VV optimization. In practice, the
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gramming iteration. Although pragmatic and prac-
tical, this is methodologically unsound. We should
also consider that, although regarded as a gold stan-
dard, echocardiographic optimization has not been
shown to improve outcomes, but appears as effective
as nominal device settings (43). Other proposed sur-
rogates of response, such as changes in LV dP/dt after
CRT do not predict outcome (44).
Automatic, device-based AV and VV optimization
has obvious practical advantages. The FREEDOM
(Frequent Optimization Study Using the QuickOpt
Method) (45) compared device-based AV/VV optimi-
zation using the QuickOpt algorithm with echocar-
diographic optimization. In this study, QuickOpt was
inferior to echocardiography. In the Smart-AV (Com-
parison of AV Optimization Methods Used in Cardiac
Resynchronization Therapy) study (43), AV optimiza-
tion by the Smart-AV algorithm did not lead to LV
reverse remodeling compared with nominal settings.
Adaptive CRT is based on an algorithm that provides
automatic selection between synchronized LV or bi-
ventricular pacing, as well as AV and VV optimization.
Although the Adaptive CRT (Adaptive Cardiac Re-
synchronization Therapy) study showed that the
algorithm was comparable to echocardiographic opti-
mization (46), it is unclear whether this beneﬁt is
attributable to AV/VV optimization or to the pacing
mode.
NONRESPONDERS
The concept of CRT nonresponders emerged from the
demonstration that 33% of patients did not exhibit a
hemodynamic response (11). We may ask, however,
why we need to measure individual response. After
all, we do not do so in the case of medical therapy or
after operations. For example, the success of a coro-
nary artery bypass operation is not deﬁned in terms of
long-term outcome. In fact, in most medical in-
terventions, the approach is to treat a population so
as to achieve an average treatment effect, even
though some patients do not respond. This may be
due to inescapable genetic factors (47). In this
context, we should consider that drugs with proven
prognostic beneﬁts do not necessarily improve
symptoms. Using the deﬁnition of response as an
improvement by $1 NYHA functional classes in HF,
the nonresponder rate is 53.3% for enalapril (48), 79%
for bisoprolol (49), and 59% for spironolactone (50).
One difﬁculty in assessing a prognostic response is
the lack of an adequate surrogate. In this respect, LV
reverse remodeling is a potential candidate because it
predicts cardiovascular mortality with a sensitivity of87% and a speciﬁcity of 69% (51). Although this may
seem statistically acceptable, some patients could be
wrongly classiﬁed as prognostic nonresponders.
Importantly, LV reverse remodeling does not predict
a symptomatic response (51).
Other proposed surrogates are more troublesome.
Peak VO2 only weakly predicts mortality in HF, and
the cutoff for predicting survival has not been deﬁned
(52). Moreover, it correlates poorly with symptoms
and not at all with quality of life (53). In contrast,
natriuretic peptides predict the outcome of CRT, but
intraindividual variations are high, even in healthy
individuals. Such “noise” limits their use in clinical
management.
Reduced response to CRT is seen with increasing
scar burden (54), posterolateral (55) and mid-wall (56)
scar location, and extreme mechanical dyssynchrony
(57). Comorbidities such as severe RV dysfunction,
pulmonary hypertension, end-stage renal failure, and
valvular disease also appear to diminish response.
Importantly, because none of these factors have been
assessed in relation to OPT control patients, we
cannot ascertain whether they completely negate the
effects of CRT. We should also consider that pre-
venting deterioration also amounts to a response, but
this has never been quantiﬁed. On the other hand,
female sex (58,59) and a nonischemic HF etiology (56)
are associated with better CRT outcomes.
THE ROLE OF IMAGING
DYSSYNCHRONY IMAGING. The ﬁnding that me-
chanical resynchronization paralleled a beneﬁt from
CRT formed the basis for dyssynchrony assessment in
patient selection. Many echocardiographic measures
of mechanical dyssynchrony once held promise as
predictors of response to CRT in single-center
studies. Their utility was then tested by the
PROSPECT (Predictors of Response to CRT) trial (60).
Even after validation by blinded core laboratories, no
echocardiographic measure of dyssynchrony could
reliably predict the response to CRT. Negative evi-
dence also comes from the recent EchoCRT study,
which failed to show a beneﬁt from CRT-D in patients
with QRS duration #130 ms and dyssynchrony
assessed echocardiographically (42). Accordingly,
all clinical guidelines have abandoned echocardio-
graphic measures of dyssynchrony.
Mechanical dyssynchrony also can be measured
using cardiac magnetic resonance (CMR). Myocardial
“tagging” is the most powerful technique for the
study of myocardial motion in humans, but it is labo-
rious, time-consuming, and not clinically applicable.
Although CMR-derived measures of mechanical
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(57), they have not been externally validated.
There remains something fundamentally elusive
about using mechanical dyssynchrony in predicting
the response to CRT. In this respect, mechanical
dyssynchrony is not only due to conduction distur-
bances, but also to other myocardial wall properties,
such as perfusion, viability, and passive motion due
to tethering by neighboring myocardial segments
within an extraordinarily complex architecture of
myocardial ﬁbers. As a methodological limitation,
mechanical dyssynchrony measures generally reﬂect
the temporal dispersion of cardiac events, but not
their magnitude or hemodynamic effects.
IMAGING TO GUIDE LV PACING. Although dyssyn-
chrony imaging may not have a role in patient selec-
tion, it may be useful in LV lead deployment. As
discussed in the following, the TARGET (Targeted Left
Ventricular Lead Placement to Guide Cardiac
Resynchronization Therapy) study (61) and STARTER
(Speckle Tracking Assisted Resynchronization Ther-
apy for Electrode Region) trial (62) suggested that
targeting late-activated segments using echocardiog-
raphymay improve outcomes. Imaging of the coronary
veins by computed tomography may also be useful in
guiding implantation. On the other hand, CMR can be
used to guide LV leads away from scars (63). A role for
electroanatomic and ECG body surface mapping is also
emerging. Image fusion could allow real-time, multi-
modality targeting of LV pacing sites. Computational
modeling (64) could predict the effects of different
pacing sites in individual patients.
SCAR BURDEN. CMR (65,66) and nuclear imaging
(54) studies have shown that scar burden is higher in
nonresponders than in responders (65,66). So far,
however, the critical cutoff for scar burden has not
been identiﬁed or validated.
HEMODYNAMICS AND RESPONSE
Conceptually, an acute hemodynamic response should
predict the outcome of CRT. In a recent study, the
change in LV dP/dtmax at the time of CRT implantation
predicted LV reverse remodeling (67). The absolute
change was small and, arguably, difﬁcult to use in
clinical practice. Other studies have shown that it is not
the change in LV dP/dtmax with CRT, but the absolute
pre-implantation value that predicts outcome (44).
This, however, has not been externally validated.
QRS COMPLEX AND RESPONSE
With respect to the lower cutoff of QRS duration, a
meta-analysis of individual patient data from majorCRT trials conﬁrms a survival beneﬁt at a QRS
duration >140 ms, with less clear beneﬁt between
120 and 140 ms (68). In a post-hoc analysis of the
REVERSE study (69), clinical response correlated
positively with QRS duration beyond 120 ms
(Central Illustration). The arbitrary cutoff of a QRS
duration $120 ms chosen by landmark trials
(19,21,26,70) is cunningly close.
Post-hoc analyses of both the REVERSE (69) and
MADIT-CRT (71) studies suggested a reduced beneﬁt
in patients with non-LBBB QRS morphology. How-
ever, a meta-analysis of individual patient data from
CRT trials has shown that LBBB morphology is not
an independent predictor of outcome (68). Notwith-
standing, current guidelines adopt LBBB as the pri-
mary substrate for CRT.
TARGETING THE LV PACING SITE
The wholly transvenous technique for CRT im-
plantation remains virtually unchanged since it
was ﬁrst described in 1994 (9). Most implanters are
satisﬁed with a good angiographic result, that is,
a posterolateral position with acceptable pacing
parameters and no diaphragmatic stimulation. In
some studies, however, the position of the LV lead
over the LV free wall, avoiding anterior or inferior
positions, does not inﬂuence outcome of CRT (72),
whereas in others, an apical position appears less
favorable (73).
Even when the LV lead is deployed in a “good”
ﬂuoroscopic position, the response is variable. This
is, perhaps, not surprising because ﬂuoroscopy is
opaque to properties of the myocardium that govern
the LV pacing response. A concept has evolved
according to which targeting segments of latest LV
“activation” improves response. The STARTER trial
(62) showed that deploying LV leads in late-activated
segments reduced the risk of death or HF hospi-
talization. However, exact concordance between
late-activated segments and LV lead position was
achieved in only 30% of patients. Furthermore, seg-
ments with likely scar were regarded as missing data.
Therefore, we cannot ascertain whether these results
were inﬂuenced by avoiding scar or by targeting late-
activated segments.
Viability in the paced LV segment could also
inﬂuence the CRT outcome. In this regard, pacing scar
is associated with a worse response (66,74) than
pacing viable myocardium. Increasing scar trans-
murality (66) and scar density (54) also portend a
worse response. Use of CMR to avoid scar appears to
improve the response to CRT (63), but this strategy
has not been externally validated.
CENTRAL ILLUSTRATION Relation Between QRS Duration and the Response and Outcome of Cardiac Resynchronization Therapy
(Left) Taken from a meta-analysis of individual patient data from landmark cardiac resynchronization therapy (CRT) trials showing hazard ratios (y-axis and solid purple
line) 95% conﬁdence interval (CI) (blue shading) for effects on total mortality of CRT versus control patients, with QRS duration plotted on the x-axis using spline
smoothing. The intersection between the solid purple line and the vertical dashed line at a hazard ratio of 1.0 (no effect) denotes the QRS duration above which there is
a high certainty of response. Adapted from Cleland et al. (68). (Right) Data from a subanalysis of the REVERSE study showing the proportion of patients with an
improved clinical response (CRT in solid gold line and control in dashed gold line) and the absolute change in left ventricular end-systolic volume index (LVESVi) at
12 months (CRT in solid blue line and control patients in dashed blue line). The curves use spline smoothing. Adapted with permission from Gold et al. (69). Note that,
combined, these data point toward a lower QRS duration of 120 ms for a beneﬁt from CRT.
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1053MULTISITE LV PACING. Advantages of multipolar
LV leads include avoidance of diaphragmatic stim-
ulation and availability of multiple pacing vectors,
which, speculatively, could permit targeting toward
viable and/or late-activated myocardium at im-
plantation and thereafter. Studies on multiple LV
leads (75) loosely support this concept, but fur-
ther studies are needed to determine whether a
multipolar approach improves CRT outcomes. Not-
withstanding, multipolar LV leads are a “game
changer” and, purely because of implanters’ pref-
erence, are likely to render conventional leads
obsolete.
ELECTROANATOMIC MAPPING. Electroanatomic map-
ping has shown that in an LBBB, LV activation is
typically U shaped, with a line of functional block that
assumes a basolateral or mid-anterior position,
depending on QRS duration (76). Importantly, CRT
modiﬁes functional blocks, which are associated with
mechanical dyssynchrony. Whether electroanatomic
mapping has a place in assessing nonresponders to
CRT requires further study. Further research on
surface electrocardiographic mapping (77) is also
required.ENDOCARDIAL LV PACING. In animal models,
endocardial LV pacing produces more rapid depolar-
ization and probably more effective resynchroni-
zation than epicardial pacing. In humans, LV
endocardial pacing improves resynchronization and
systolic function, but a clinical beneﬁt has not been
shown (78). Transeptal/transmitral and transapical
endocardial LV pacing remains experimental. The
WiSE-CRT (Wireless Stimulation Endocardially for
CRT) study (79) recently demonstrated the feasibility
of endocardial stimulation for CRT with a leadless
ultrasound-based technology.
DELIVERY OF CRT IN THE REAL WORLD
In a nested case-control study in the IMPROVE HF
study (IMPROVE HF: Registry to Improve the Use of
Evidence-Based Heart Failure Therapies in the
Outpatient Setting) (80), device therapy added an
incremental survival beneﬁt to OPT in advanced HF
(Figure 3A). Additionally, recent evidence shows that
CRT can retard disease progression in mild HF
(24,26), yet CRT uptake is low (Figure 3B) (81).
HF has devastating effects on survival and quality
of life. In the CARE-HF study, the annual mortality
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FIGURE 3 Incremental Beneﬁt of Device Therapy and Reasons for Nonimplantation in Patients With HF
(A) The cumulative percentage of reduction in the odds of death at 24 months associated with sequential treatments compared with no
treatment among patients eligible for all 4 therapies (N ¼ 368). Reprinted with permission from Fonarow et al. (80). (B) Reasons for non-
implantation in 12,440 hospitalized or ambulatory patients with heart failure (HF) in the European Society of Cardiology Long-Term Registry.
The most common reason for nonimplantation of a device, when clinically indicated, was physician uncertainties about the indication. ACEI ¼
angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BB ¼ beta-blocker; CRT ¼ cardiac resynchronization therapy;
ICD ¼ implantable cardioverter-deﬁbrillator. Reproduced with permission from Maggioni et al. (81).
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1054rate in the non-CRT group was 12.6% (21), which is
worse than for regional colonic carcinoma and other
cancers. For a condition comparable to cancer in
survival terms, we are far from matching the ﬁeld of
oncology in offering this therapy to all eligible
patients with advanced, let alone early, disease. In
this context, however, we should consider that CRT
involves complications (82).
An obstacle in therapy delivery is the disconnec-
tion between HF and electrophysiology ﬁelds. We
need a multidisciplinary approach and a shift from
electrophysiology to HF (or vice versa). As in
oncology, we need to systematically “capture”
patients from our specialty and other specialties,
including general practice. Computerized alerts on
QRS duration and LV function, throughout secondary
and primary care, are likely to bear fruit.
HEALTH ECONOMICS
The cost of interventions has to match the “willing-
ness to pay.” The incremental cost-effectivenessratio (ICER), or the additional cost of a quality-
adjusted life-year saved, is a widely accepted mea-
sure of the cost of medical interventions. Acceptable
ICERs are <$50,000 (V35,920) in the United States
and <$55,677 (V40,000) in Europe.
The wealth of economic data available in the ﬁeld of
device therapy reﬂects the commitment of the
specialty to health economics. A simulation model
using a lifetime horizon, on the basis of advanced HF
patient data from the CARE-HF and COMPANION
studies, yielded an ICER $10,143 (V7,538) for CRT-P
and $24,243 (V18,017) for CRT-D compared with
OPT (83). For mild HF, a MADIT-CRT analysis
(84) yielded an ICER for CRT-D of $58,330 compared
with ICD implantation. A longer time horizon and a
pre-implantation LBBB reduced the ICER to $7,320.
Similar ﬁgures have emerged from the REVERSE
study (85). Over a 10-year time horizon, CRT-on was
associated with an ICER of V14,278 per quality-
adjusted life-year. Together, these studies demon-
strate that CRT-P and CRT-D are as cost-effective as
many other medical interventions (Figure 4) (86–93).
115Enalapril for heart failure
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FIGURE 4 Comparative Cost-Effectiveness of Device Therapy
Cost per quality-adjusted life-year (QALY) for device therapy and other therapies. Currency conversion: 1 GBP ¼ $1.9976, V1.4841. See the
Online Appendix for references. ACEI ¼ angiotensin-converting enzyme inhibitor; AF ¼ atrial ﬁbrillation; CRT-D ¼ cardiac resynchronization
therapy–deﬁbrillation; CRT-P ¼ cardiac resynchronization therapy–pacing; LVAD ¼ left ventricular assist device; LVH ¼ left ventricular hy-
pertrophy; TAVI ¼ transcatheter aortic valve implantation.
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1055CONCLUSIONS
The invention of CRT can be traced to the demon-
stration from almost a century ago of a link between
conduction disturbances and impaired LV function.
A small community of clinical electrophysiologists,
engineers, and industry initially developed this
technology. Throughout the past 20 years, a proof-of-
concept culminated in robust clinical trials. As it
currently stands, CRT is a clinically and cost-effective
treatment for patients with both advanced and mild
HF and a wide (intrinsic or paced) QRS complex.
Speculatively, biventricular pacing may someday
replace RV pacing.Although implantation and subsequent optimiza-
tion could be reﬁned, present-day CRT has been as
revolutionary as drug therapy for selected patients
with HF. Our attention should be directed toward
increasing its delivery. To “getwith the guidelines,”we
need to increase awareness outside the ﬁeld of elec-
trophysiology. Most importantly, we will need a team
effort from electrophysiologists and HF specialists.
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